The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Annual Conference 2022

Towards a Collaborative Future in Patient Access

7-9 February 2022, Noordwijk (NL)

 

 

EVENT OUTLINE 

The  Cancer Drug Development Forum (CDDF) Annual conference is a unique meeting that gathers the leaders in the world of innovative cancer therapy development, including medical researchers, pharmaceutical industry representatives, regulatory authority representatives and patient advocacy groups. In 2022, the annual conference will be organised in a hybrid format from 7 to 9 February 2022 in Noordwijk aan Zee (NL).

This multi-stakeholder, interactive meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities. The programme will focus on the way towards a collaborative future in patient access with a special emphasis on the following topics:

  • Integration of Regulatory Assessment and the Assessment of Reimbursement 
  • Enhancing the Future of Clinical Trials
  • Lessons learned from Acceleration in Pediatric Oncology Programs
  • Collaboration in the Post-Covid Regulatory Environment.   

 

PROGRAMME COMMITTEE
  •  Jaap Verweij (CDDF Board, NL)
  • Claudia Hey (Merck Healthcare KGaA, DE)
  • Michael Zaiac (Novartis, CH)
  • Roger Wilson (WECAN / SPAEN, UK)
  • Kim H. Lyerly (AAADV, US)

 

COMMITTEE ADVISOR
  • Ralf Herold (EMA, DE)

 

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs and patient advocates.

 

DRAFT PROGRAMME 

To view the draft programme, click HERE

 

MEETING VENUE 

TBC

 

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70